Pfizer logo

Pfizer

PFIZER NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹18,698 Cr
Volatility
Low Risk
P/E Ratio
25.27
EBITDA
₹1,092 Cr
Return on Equity
17.19%
Debt to Equity
0.02
Book Value
₹918.71
EPS
₹131.73
52W High
₹5,578.5
52W Low
₹4,080

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

3
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 58.3%

Weaknesses

1
  • The company has delivered a poor sales growth of 2.39% over past five years.

Growth Rate

Revenue Growth
10.35% higher than 3Y
Net Income Growth
-5.89% lower than 3Y
Cash Flow Change
46.66% lower than 3Y
ROE
-5.55% lower than 3Y
ROCE
-2.8% lower than 3Y
EBITDA Margin (Avg.)
8.44% lower than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 2d ago
AI opinion · based on fundamentals
Risk medium

Pfizer Ltd trades at a market cap of ₹18,698 Cr with a PE of 25.5x and a dividend yield of 1.83%. The company is virtually debt-free with a consistent ROE of 16-18% over the past decade, but top-line growth has been sluggish at a 5-year sales CAGR of just 2%.

Bull Case 7
  • Company is almost debt-free, giving it a clean balance sheet and financial flexibility to invest in growth or return capital to shareholders
  • Consistent ROE averaging 17% over 10 years and 18% in the last year, indicating efficient capital allocation relative to equity
  • Healthy dividend payout ratio of 58.3%, rewarding shareholders with a current dividend yield of 1.83%
  • Compounded profit growth of 14% on a TTM basis and 10% over 10 years shows steady earnings expansion despite tepid revenue growth
  • TTM sales growth has accelerated to 11%, a notable improvement over the 1% and 2% CAGR seen over 3-year and 5-year periods respectively
  • Price-to-book ratio of 4.46x is supported by an 18% last-year ROE, suggesting the premium is backed by return generation rather than mere sentiment
  • Backed by global parent Pfizer Inc., providing access to a strong R&D pipeline, established brands, and global best practices in pharmaceutical manufacturing
Bear Case 7
  • Five-year compounded sales growth of only 2% signals persistent top-line stagnation and limited volume or pricing power
  • Stock price CAGR of -21% over the past 1 year and -8% over 5 years reflects significant erosion of shareholder value
  • PE of 25.5x appears elevated for a company delivering just 2% revenue CAGR over 5 years, implying the stock is priced for growth that has not materialized on the top line
  • Three-year compounded sales growth of just 1% suggests the recent TTM uptick to 11% may not yet represent a sustainable trend
  • Three-year stock price CAGR of only 2% has significantly underperformed broader Indian market indices over the same period
  • As a subsidiary of a global MNC, strategic decisions on product launches, pricing, and capital allocation are controlled by the parent, limiting minority shareholder influence
  • 52-week high and low data are unavailable (reported as 0), but the -21% one-year stock CAGR indicates the stock is well off its recent peaks

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 2h ago
Neutral 2
  • Minipress XL sales discontinued Sep 7

    Pfizer Ltd discontinues Minipress XL sales effective Sep 7, 2026 after Pfizer Inc. USA halted manufacture. The company will receive a $13.9 million (~₹131.38 crore) lump sum payment, approved by the Board on Sep 7, 2026.

  • VRS payout ruled non-taxable Aug 27

    Pune ITAT ruled that a ₹65.21 lakh payout to a former Pfizer Healthcare India employee under a voluntary retirement scheme is a capital receipt and not taxable, following consistent precedent in similar Pfizer cases. The ruling was delivered on Jun 8, 2026 for AY 2019-20.

TL;DR: A quiet period for Pfizer Ltd with no material headwinds or bullish catalysts. The Minipress XL discontinuation is offset by a ₹131.38 crore lump sum payment, making it largely neutral to financials. The ITAT ruling on VRS payouts is a legacy matter with no direct impact on the listed entity. Overall trend is stable with no clear directional signal.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
531
575
540
547
563
589
538
592
603
642
645
629
653
Expenses
421
393
387
357
385
399
392
364
393
412
417
393
406
Operating Profit
111
183
153
189
177
189
146
228
210
230
228
236
248
OPM %
21%
32%
28%
35%
32%
32%
27%
38%
35%
36%
35%
38%
38%
Other Income
33
36
44
75
42
43
43
217
67
42
-20
50
45
Interest
3
3
3
7
2
2
2
3
3
2
2
2
1
Depreciation
16
15
18
14
15
15
15
16
14
14
14
15
14
PBT
126
201
176
244
203
215
172
426
260
255
192
269
277
Tax %
26%
26%
26%
27%
26%
26%
26%
22%
26%
26%
26%
26%
26%
Net Profit
94
149
130
179
151
158
128
331
192
189
142
200
204
EPS in Rs
20.44
32.56
28.41
39.1
32.94
34.61
27.89
72.34
41.91
41.32
31
43.68
44.7
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,853
2,012
1,966
1,969
2,082
2,152
2,239
2,611
2,425
2,193
2,281
2,520
2,570
Expenses
1,438
1,579
1,616
1,468
1,516
1,578
1,526
1,775
1,616
1,555
1,540
1,615
1,628
Operating Profit
414
433
350
501
566
574
712
836
809
638
742
904
942
OPM %
22%
22%
18%
25%
27%
27%
32%
32%
33%
29%
33%
36%
37%
Other Income
44
97
232
114
167
183
81
63
134
185
344
139
116
Interest
2
1
2
1
2
11
15
11
13
15
8
10
8
Depreciation
250
58
63
66
71
103
109
115
106
62
61
58
58
PBT
207
470
517
548
660
642
669
773
824
746
1,016
976
993
Tax %
66%
35%
35%
34%
35%
21%
26%
21%
24%
26%
24%
26%
—
Net Profit
70
305
337
360
429
509
498
613
624
551
768
722
735
EPS in Rs
15.26
66.67
73.62
78.71
93.79
111
109
134
136
121
168
158
161
Div. Payout %
82%
22%
27%
25%
24%
297%
32%
26%
29%
29%
98%
48%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
46
46
46
46
46
46
46
46
46
46
46
46
Reserves
1,927
2,118
2,373
2,637
2,966
3,350
2,347
2,819
3,162
3,550
4,172
4,157
Borrowings
2
2
2
2
2
2
63
39
41
40
108
70
Other Liabilities
638
722
840
1,004
926
1,007
810
997
752
593
585
649
Total Liabilities
2,614
2,888
3,261
3,690
3,940
4,405
3,266
3,901
4,001
4,229
4,911
4,922
Fixed Assets
944
925
902
950
886
973
894
869
749
713
724
678
CWIP
13
3
15
1
0
1
3
1
8
0
8
20
Investments
43
37
0
0
0
0
0
0
0
0
0
0
Other Assets
1,614
1,923
2,343
2,739
3,054
3,432
2,369
3,030
3,244
3,516
4,180
4,224
Total Assets
2,614
2,888
3,261
3,690
3,940
4,405
3,266
3,901
4,001
4,229
4,911
4,922
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
113
345
329
332
98
323
427
667
356
257
660
968
Investing
68
-701
-250
-238
35
1,530
-469
-575
-36
54
-71
-562
Financing
-1
-62
-83
-110
-110
-164
-1,571
-181
-346
-235
-205
-798
Net Cash Flow
181
-417
-3
-17
23
1,690
-1,613
-88
-26
75
383
-392
Free Cash Flow
93
398
394
262
125
343
410
654
292
291
783
944
CFO/OP
62
120
146
105
59
93
89
107
81
64
110
105
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
32
26
20
29
30
29
18
20
23
31
31
26
Inventory Days
191
167
148
147
189
198
199
173
175
200
214
195
Days Payable
165
157
178
245
213
197
130
102
91
77
68
89
Cash Conversion Cycle
58
36
-10
-69
6
31
87
91
107
154
177
132
Working Capital Days
7
-9
-47
-57
-16
-8
3
-14
1
24
23
9
ROCE %
24%
22%
17%
21%
23%
20%
23%
29%
26%
22%
21%
24%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Pfizer insights

65 extracted metrics + investor summaries across FY06–FY26.

Log in — free

Shareholding Pattern

FIIs1.65%Promot.63.92%Others4.59%Public12.04%DIIs17.80%As ofJun 2026

Documents

Frequently Asked Questions about Pfizer

What does Pfizer Ltd do?
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors...
Where is Pfizer Ltd (PFIZER) listed?
Pfizer Ltd trades as PFIZER on the NSE and under code 500680 on the BSE.
Which sector does Pfizer Ltd belong to?
Pfizer Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Pfizer Ltd?
Pfizer Ltd has a market capitalisation of ₹18,698 Cr, which places it in the Mid Cap band.
What is the PE ratio of Pfizer Ltd?
Pfizer Ltd trades at a PE ratio of 25.27, on earnings per share of ₹131.73, against a book value of ₹918.71 per share.
What is the 52-week high and low of Pfizer Ltd?
Over the last 52 weeks Pfizer Ltd has traded between ₹4,080 and ₹5,578.5.
Does Pfizer Ltd pay dividends?
Pfizer Ltd has a dividend yield of 1.83%.
What is the Return on Equity (ROE) of Pfizer Ltd?
Pfizer Ltd reported a return on equity of 17.19%. Its debt-to-equity ratio is 0.02.

Company Information

Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India.[1] It is the 3rd largest multinational pharmaceutical company in India.[2]

Website pfizerindia.com
CEO Ms. Meenakshi Nevatia
Employees 1,598
Listed 1999-04-28
Face Value ₹ 10
Issued Size 4,57,47,732

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/PFIZER.md for Pfizer Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List